1 | all | 131,254 |
2 | 2594 | 7 |
3 | 1,795 | 6 |
4 | 2944 | 6 |
5 | cyp1b1*2 | 6 |
6 | nder | 5 |
7 | 11/49 | 4 |
8 | 2,673 | 4 |
9 | 2,843 | 4 |
10 | 4,881 | 4 |
11 | 4745 | 4 |
12 | berinert | 4 |
13 | ivr+ | 4 |
14 | mlpa-negative | 4 |
15 | 11,827 | 3 |
16 | 2628 | 3 |
17 | 3,246 | 3 |
18 | 3846 | 3 |
19 | 3916 | 3 |
20 | 4,115 | 3 |
21 | 4,558 | 3 |
22 | 4912 | 3 |
23 | 5,697 | 3 |
24 | 5057 | 3 |
25 | 5104 | 3 |
26 | 5222 | 3 |
27 | 5284 | 3 |
28 | 5472 | 3 |
29 | 'larger | 2 |
30 | 10,245 | 2 |
31 | 11,560 | 2 |
32 | 12,367 | 2 |
33 | 16,751 | 2 |
34 | 17,732 | 2 |
35 | 18,585 | 2 |
36 | 2,912 | 2 |
37 | 21,272 | 2 |
38 | 21,295 | 2 |
39 | 25,500 | 2 |
40 | 2777 | 2 |
41 | 3,097 | 2 |
42 | 3594 | 2 |
43 | 4,612 | 2 |
44 | 4795 | 2 |
45 | 4987 | 2 |
46 | 5,829 | 2 |
47 | 5,916 | 2 |
48 | 5309 | 2 |
49 | 5603 | 2 |
50 | 5945 | 2 |
51 | 6101 | 2 |
52 | 6674 | 2 |
53 | 7,229 | 2 |
54 | 7236 | 2 |
55 | 7829 | 2 |
56 | 7984 | 2 |
57 | 8032 | 2 |
58 | autologous-hct | 2 |
59 | bm+pbpc | 2 |
60 | bsr-cosp-cmha | 2 |
61 | calcium-stone | 2 |
62 | drotaa-treated | 2 |
63 | folfox-treated | 2 |
64 | group-incentive | 2 |
65 | matched-group | 2 |
66 | non-cdh | 2 |
67 | oct-negative | 2 |
68 | panic/agoraphobia | 2 |
69 | performance-approach-oriented | 2 |
70 | rdt-negative | 2 |
71 | re+ | 2 |
72 | results-of | 2 |
73 | ustekinumab-randomized | 2 |
74 | 10,194 | 1 |
75 | 10-20-year-old | 1 |
76 | 10.9g/l | 1 |
77 | 11,223 | 1 |
78 | 11,877 | 1 |
79 | 12,371 | 1 |
80 | 13,382 | 1 |
81 | 15486 | 1 |
82 | 18,060 | 1 |
83 | 18.2mg | 1 |
84 | 20-60min/session | 1 |
85 | 21,345 | 1 |
86 | 22,933 | 1 |
87 | 27,196 | 1 |
88 | 28,072 | 1 |
89 | 299,000 | 1 |
90 | 4706 | 1 |
91 | 5,928 | 1 |
92 | 613,000 | 1 |
93 | 74,155 | 1 |
94 | 7722 | 1 |
95 | 8279 | 1 |
96 | ad-positive | 1 |
97 | adionectin | 1 |
98 | ava-treated | 1 |
99 | baclofen-treated | 1 |
100 | cin3+after | 1 |
101 | com-on-p. | 1 |
102 | cutamesine-treated | 1 |
103 | fourty- | 1 |
104 | gs-9411-treated | 1 |
105 | guilty-informed | 1 |
106 | haloperidol-controlled | 1 |
107 | hc2-negative | 1 |
108 | high-acculturation | 1 |
109 | high-depression | 1 |
110 | interaction-related | 1 |
111 | intralymphocytic | 1 |
112 | lipus-treated | 1 |
113 | low-depression | 1 |
114 | low-relevance | 1 |
115 | masta-agonist | 1 |
116 | neurodevelopment.growth | 1 |
117 | non-apatite | 1 |
118 | non-azoospermic | 1 |
119 | nonstarved | 1 |
120 | nr-chc | 1 |
121 | one-in-ten | 1 |
122 | overexposed | 1 |
123 | psacwy-naïve | 1 |
124 | psychodermatology | 1 |
125 | self-object | 1 |
126 | shile | 1 |
127 | sixty-one-point | 1 |
128 | steroid-3-sulfates | 1 |
129 | train-of | 1 |
130 | treatmentnaïve | 1 |
131 | user-caregiver | 1 |
132 | vowel-deletions | 1 |
133 | wattmax | 1 |
1 | 'larger | 2 |
2 | 1,795 | 6 |
3 | 10,194 | 1 |
4 | 10,245 | 2 |
5 | 10-20-year-old | 1 |
6 | 10.9g/l | 1 |
7 | 11,223 | 1 |
8 | 11,560 | 2 |
9 | 11,827 | 3 |
10 | 11,877 | 1 |
11 | 11/49 | 4 |
12 | 12,367 | 2 |
13 | 12,371 | 1 |
14 | 13,382 | 1 |
15 | 15486 | 1 |
16 | 16,751 | 2 |
17 | 17,732 | 2 |
18 | 18,060 | 1 |
19 | 18,585 | 2 |
20 | 18.2mg | 1 |
21 | 2,673 | 4 |
22 | 2,843 | 4 |
23 | 2,912 | 2 |
24 | 20-60min/session | 1 |
25 | 21,272 | 2 |
26 | 21,295 | 2 |
27 | 21,345 | 1 |
28 | 22,933 | 1 |
29 | 25,500 | 2 |
30 | 2594 | 7 |
31 | 2628 | 3 |
32 | 27,196 | 1 |
33 | 2777 | 2 |
34 | 28,072 | 1 |
35 | 2944 | 6 |
36 | 299,000 | 1 |
37 | 3,097 | 2 |
38 | 3,246 | 3 |
39 | 3594 | 2 |
40 | 3846 | 3 |
41 | 3916 | 3 |
42 | 4,115 | 3 |
43 | 4,558 | 3 |
44 | 4,612 | 2 |
45 | 4,881 | 4 |
46 | 4706 | 1 |
47 | 4745 | 4 |
48 | 4795 | 2 |
49 | 4912 | 3 |
50 | 4987 | 2 |
51 | 5,697 | 3 |
52 | 5,829 | 2 |
53 | 5,916 | 2 |
54 | 5,928 | 1 |
55 | 5057 | 3 |
56 | 5104 | 3 |
57 | 5222 | 3 |
58 | 5284 | 3 |
59 | 5309 | 2 |
60 | 5472 | 3 |
61 | 5603 | 2 |
62 | 5945 | 2 |
63 | 6101 | 2 |
64 | 613,000 | 1 |
65 | 6674 | 2 |
66 | 7,229 | 2 |
67 | 7236 | 2 |
68 | 74,155 | 1 |
69 | 7722 | 1 |
70 | 7829 | 2 |
71 | 7984 | 2 |
72 | 8032 | 2 |
73 | 8279 | 1 |
74 | ad-positive | 1 |
75 | adionectin | 1 |
76 | all | 131,254 |
77 | autologous-hct | 2 |
78 | ava-treated | 1 |
79 | baclofen-treated | 1 |
80 | berinert | 4 |
81 | bm+pbpc | 2 |
82 | bsr-cosp-cmha | 2 |
83 | calcium-stone | 2 |
84 | cin3+after | 1 |
85 | com-on-p. | 1 |
86 | cutamesine-treated | 1 |
87 | cyp1b1*2 | 6 |
88 | drotaa-treated | 2 |
89 | folfox-treated | 2 |
90 | fourty- | 1 |
91 | group-incentive | 2 |
92 | gs-9411-treated | 1 |
93 | guilty-informed | 1 |
94 | haloperidol-controlled | 1 |
95 | hc2-negative | 1 |
96 | high-acculturation | 1 |
97 | high-depression | 1 |
98 | interaction-related | 1 |
99 | intralymphocytic | 1 |
100 | ivr+ | 4 |
101 | lipus-treated | 1 |
102 | low-depression | 1 |
103 | low-relevance | 1 |
104 | masta-agonist | 1 |
105 | matched-group | 2 |
106 | mlpa-negative | 4 |
107 | nder | 5 |
108 | neurodevelopment.growth | 1 |
109 | non-apatite | 1 |
110 | non-azoospermic | 1 |
111 | non-cdh | 2 |
112 | nonstarved | 1 |
113 | nr-chc | 1 |
114 | oct-negative | 2 |
115 | one-in-ten | 1 |
116 | overexposed | 1 |
117 | panic/agoraphobia | 2 |
118 | performance-approach-oriented | 2 |
119 | psacwy-naïve | 1 |
120 | psychodermatology | 1 |
121 | rdt-negative | 2 |
122 | re+ | 2 |
123 | results-of | 2 |
124 | self-object | 1 |
125 | shile | 1 |
126 | sixty-one-point | 1 |
127 | steroid-3-sulfates | 1 |
128 | train-of | 1 |
129 | treatmentnaïve | 1 |
130 | user-caregiver | 1 |
131 | ustekinumab-randomized | 2 |
132 | vowel-deletions | 1 |
133 | wattmax | 1 |
1 | re+ | 2 |
2 | ivr+ | 4 |
3 | fourty- | 1 |
4 | com-on-p. | 1 |
5 | 613,000 | 1 |
6 | 299,000 | 1 |
7 | 25,500 | 2 |
8 | 18,060 | 1 |
9 | 11,560 | 2 |
10 | 6101 | 2 |
11 | 16,751 | 2 |
12 | 12,371 | 1 |
13 | 4,881 | 4 |
14 | cyp1b1*2 | 6 |
15 | 4,612 | 2 |
16 | 2,912 | 2 |
17 | 4912 | 3 |
18 | 5222 | 3 |
19 | 7722 | 1 |
20 | 8032 | 2 |
21 | 17,732 | 2 |
22 | 28,072 | 1 |
23 | 21,272 | 2 |
24 | 5472 | 3 |
25 | 13,382 | 1 |
26 | 5603 | 2 |
27 | 11,223 | 1 |
28 | 22,933 | 1 |
29 | 2,843 | 4 |
30 | 2,673 | 4 |
31 | 5104 | 3 |
32 | 2944 | 6 |
33 | 6674 | 2 |
34 | 5284 | 3 |
35 | 7984 | 2 |
36 | 10,194 | 1 |
37 | 2594 | 7 |
38 | 3594 | 2 |
39 | 4,115 | 3 |
40 | 10,245 | 2 |
41 | 21,345 | 1 |
42 | 4745 | 4 |
43 | 5945 | 2 |
44 | 74,155 | 1 |
45 | 18,585 | 2 |
46 | 21,295 | 2 |
47 | 1,795 | 6 |
48 | 4795 | 2 |
49 | 4706 | 1 |
50 | 5,916 | 2 |
51 | 3916 | 3 |
52 | 7236 | 2 |
53 | 3,246 | 3 |
54 | 3846 | 3 |
55 | 15486 | 1 |
56 | 27,196 | 1 |
57 | 11,827 | 3 |
58 | 5057 | 3 |
59 | 12,367 | 2 |
60 | 2777 | 2 |
61 | 11,877 | 1 |
62 | 4987 | 2 |
63 | 3,097 | 2 |
64 | 5,697 | 3 |
65 | 2628 | 3 |
66 | 5,928 | 1 |
67 | 4,558 | 3 |
68 | 5309 | 2 |
69 | 7,229 | 2 |
70 | 5,829 | 2 |
71 | 7829 | 2 |
72 | 11/49 | 4 |
73 | 8279 | 1 |
74 | bsr-cosp-cmha | 2 |
75 | panic/agoraphobia | 2 |
76 | nr-chc | 1 |
77 | non-azoospermic | 1 |
78 | intralymphocytic | 1 |
79 | bm+pbpc | 2 |
80 | haloperidol-controlled | 1 |
81 | guilty-informed | 1 |
82 | overexposed | 1 |
83 | gs-9411-treated | 1 |
84 | drotaa-treated | 2 |
85 | ava-treated | 1 |
86 | cutamesine-treated | 1 |
87 | baclofen-treated | 1 |
88 | lipus-treated | 1 |
89 | folfox-treated | 2 |
90 | interaction-related | 1 |
91 | performance-approach-oriented | 2 |
92 | nonstarved | 1 |
93 | ustekinumab-randomized | 2 |
94 | 10-20-year-old | 1 |
95 | low-relevance | 1 |
96 | shile | 1 |
97 | calcium-stone | 2 |
98 | non-apatite | 1 |
99 | hc2-negative | 1 |
100 | mlpa-negative | 4 |
101 | oct-negative | 2 |
102 | rdt-negative | 2 |
103 | ad-positive | 1 |
104 | group-incentive | 2 |
105 | psacwy-naïve | 1 |
106 | treatmentnaïve | 1 |
107 | train-of | 1 |
108 | results-of | 2 |
109 | 18.2mg | 1 |
110 | non-cdh | 2 |
111 | neurodevelopment.growth | 1 |
112 | 10.9g/l | 1 |
113 | all | 131,254 |
114 | one-in-ten | 1 |
115 | adionectin | 1 |
116 | high-depression | 1 |
117 | low-depression | 1 |
118 | 20-60min/session | 1 |
119 | high-acculturation | 1 |
120 | matched-group | 2 |
121 | nder | 5 |
122 | 'larger | 2 |
123 | cin3+after | 1 |
124 | user-caregiver | 1 |
125 | steroid-3-sulfates | 1 |
126 | vowel-deletions | 1 |
127 | self-object | 1 |
128 | autologous-hct | 2 |
129 | sixty-one-point | 1 |
130 | berinert | 4 |
131 | masta-agonist | 1 |
132 | wattmax | 1 |
133 | psychodermatology | 1 |